고주파 절제 기기 시장 예측(-2030년) : 제품별, 양식별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Radiofrequency Ablation Devices Market is accounted for $4.87 billion in 2023 and is expected to reach $11.41 billion by 2030 growing at a CAGR of 12.9% during the forecast period. Radiofrequency ablation devices are minimally invasive tools used in medical procedures to treat certain conditions like chronic pain or abnormal heart rhythms. These devices use high-frequency electrical currents to generate heat, which is directed to specific tissues or nerves, effectively destroying them. RFA procedures are often preferred for their precision, minimal invasiveness, and shorter recovery times compared to traditional surgical methods.

According to the WHO Global Health Expenditure Database 2021, Germany spent 12.8% of its Gross Domestic Product (GDP) on healthcare, the UK spent 11.9%, Sweden spent 11.3%, Norway spent 10.1%, and Italy spent 9.5%.

Market Dynamics:

Driver:

Rising incidences of chronic diseases

The increasing prevalence of chronic diseases, such as cancer and cardiovascular conditions, drives the demand for radiofrequency ablation devices. These devices offer minimally invasive solutions for treating chronic pain and debilitating symptoms associated with these diseases. As the aging population grows and chronic conditions become more prevalent, there is a heightened need for effective treatment options. Radiofrequency ablation procedures provide patients with a viable alternative to traditional surgery, leading to reduced hospital stays, faster recovery times, and improved quality of life, thus fueling market growth.

Restraint:

Risk of complications

The risks of complications in RFA devices include infection, nerve damage, bleeding, and rarely, damage to nearby organs. These complications can undermine patient confidence, increase healthcare costs due to additional treatments, and lead to legal liabilities for healthcare providers. Consequently, concerns regarding safety may deter patient acceptance and physician adoption of RFA procedures. Limited adoption hampers market growth by restraining procedure volumes and slowing the demand for RFA devices, impacting revenue generation for manufacturers and impeding market expansion.

Opportunity:

Growing patient preference for minimally invasive procedures

Patients increasingly seek procedures that offer reduced post-operative complications, quicker recovery times, and minimal discomfort. Radiofrequency ablation provides a minimally invasive alternative to traditional surgical methods for treating various medical conditions, fulfilling patient demand for less invasive options. As a result, the market for radiofrequency ablation devices experiences growth as healthcare providers strive to meet patient preferences for procedures that offer greater convenience, safety, and shorter recovery periods.

Threat:

Competition from alternative treatment options

Alternative treatment options to radiofrequency ablation devices include medication, physical therapy, and other minimally invasive procedures such as cryoablation and laser ablation. Competition from these alternatives offers patients and healthcare providers with additional choices for managing conditions, potentially diverting the demand. Additionally, some alternative treatments have lower upfront costs or perceived risks compared to radiofrequency ablation, making them more attractive options for certain patients or healthcare systems, thereby limiting the market potential for radiofrequency ablation devices.

Covid-19 Impact

The covid-19 pandemic has had a mixed impact on the radiofrequency ablation devices market. While the initial disruption caused by lockdowns and restrictions led to a decline in elective procedures and device sales, the gradual resumption of healthcare services and the prioritization of minimally invasive treatments have supported market recovery. Additionally, the pandemic has underscored the importance of less invasive procedures to minimize patient hospital stays and reduce the burden on healthcare systems, potentially driving further adoption of radiofrequency ablation devices in the post-pandemic era.

The multipolar segment is expected to be the largest during the forecast period

The multipolar segment is estimated to have a lucrative growth. These devices are cutting-edge tools used in minimally invasive procedures to treat various medical conditions. Multipolar RFA employs multiple electrodes to create a more extensive and controlled thermal ablation zone. This technology enables precise targeting of tissues while minimizing damage to surrounding areas. Multipolar RFA has shown promising results in treating conditions such as liver cancer, lung tumours, and chronic pain. Its versatility and efficacy make it a valuable tool in modern interventional radiology and oncology practices.

The pain management segment is expected to have the highest CAGR during the forecast period

The pain management segment is anticipated to witness the highest CAGR growth during the forecast period, due to its minimally invasive relief for chronic pain. These devices employ radiofrequency waves to target and deactivate specific nerves that transmit pain signals. By precisely targeting nerves without damaging surrounding tissue, RFA offers a low-risk alternative to surgery and medication. Its effectiveness, minimal recovery time, and ability to improve patients' quality of life make RFA devices indispensable tools in the field of pain management.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to increasing prevalence of chronic diseases, rising healthcare expenditure, and growing awareness about minimally invasive treatments. Countries like China, India, and Japan are key contributors to this growth, supported by a large patient population and improving access to healthcare services. Additionally, advancements in healthcare infrastructure and technology adoption in emerging economies further bolster demand.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to its advanced healthcare infrastructure, and favourable reimbursement policies. The United States dominates the region's market due to its large patient population and significant investments in healthcare R&D. Technological advancements and increasing adoption of minimally invasive procedures further contribute to market growth.

Key players in the market

Some of the key players profiled in the Radiofrequency Ablation Devices Market include Medtronic PLC, Boston Scientific Corporation, Abbott Laboratories, AngioDynamics Inc., Johnson & Johnson, Stryker Corporation, Merit Medical Systems Inc., Royal Philips, Olympus Corporation, Hologic Inc., Cosman Medical, RF Medical Corporation, Misonix Inc., Neomed Management AS, Diros Technology Inc., Compal Electronics, Smith & Nephew PLC, Elekta AB, CONMED Corporation and AtriCure.

Key Developments:

In April 2023, Taiwanese electronics company, Compal Electronics has expanded into the therapeutic medical device segment by introducing a new radiofrequency ablation (RFA) system called AblatePal. The new RFA system is intended for use in coagulation and ablation of soft tissue during percutaneous and intraoperative procedures, including partial or complete ablation of non-resectable liver lesions.

In April 2022, Royal Philips launched the latest release of its KODEX-EPD system, which offers enhanced imaging and mapping capabilities for RF ablation, including the new Tissue Engagement Viewer and support for Medtronic DiamondTemp ablation system.

Products Covered:

• Radiofrequency Ablation Generators
• Radiofrequency Ablation Catheters
• Radiofrequency Ablation Probes
• Radiofrequency Ablation Accessories
• Other Products

Modalities Covered:

• Unipolar
• Bipolar
• Multipolar

Applications Covered:

• Cardiology
• Oncology
• Pain Management
• Gynaecology
• Urology
• Orthopaedics
• Cosmetology
• Other Applications

End Users Covered:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Radiofrequency Ablation Devices Market, By Product

• 5.1 Introduction
• 5.2 Radiofrequency Ablation Generators
• 5.3 Radiofrequency Ablation Catheters
• 5.4 Radiofrequency Ablation Probes
• 5.5 Radiofrequency Ablation Accessories
• 5.6 Other Products

6 Global Radiofrequency Ablation Devices Market, By Modality

• 6.1 Introduction
• 6.2 Unipolar
• 6.3 Bipolar
• 6.4 Multipolar

7 Global Radiofrequency Ablation Devices Market, By Application

• 7.1 Introduction
• 7.2 Cardiology
• 7.3 Oncology
• 7.4 Pain Management
• 7.5 Gynaecology
• 7.6 Urology
• 7.7 Orthopaedics
• 7.8 Cosmetology
• 7.9 Other Applications

8 Global Radiofrequency Ablation Devices Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Ambulatory Surgical Centers
• 8.4 Specialty Clinics
• 8.5 Research Institutes
• 8.6 Other End Users

9 Global Radiofrequency Ablation Devices Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Medtronic PLC
• 11.2 Boston Scientific Corporation
• 11.3 Abbott Laboratories
• 11.4 AngioDynamics Inc.
• 11.5 Johnson & Johnson
• 11.6 Stryker Corporation
• 11.7 Merit Medical Systems Inc.
• 11.8 Royal Philips
• 11.9 Olympus Corporation
• 11.10 Hologic Inc.
• 11.11 Cosman Medical
• 11.12 RF Medical Corporation
• 11.13 Misonix Inc.
• 11.14 Neomed Management AS
• 11.15 Diros Technology Inc.
• 11.16 Compal Electronics
• 11.17 Smith & Nephew PLC
• 11.18 Elekta AB
• 11.19 CONMED Corporation
• 11.20 AtriCure